The role of BPTF in melanoma progression and in response to BRAF-targeted therapy

Journal of the National Cancer Institute

Volumn 107, Issue 5, 2015, Pages

  Dar, Altaf A ^a   Nosrati, Mehdi ^a   Bezrookove, Vladimir ^a   De Semir, David ^a   Majid, Shahana ^b   Thummala, Suresh ^a   Sun, Vera ^a   Tong, Schuyler ^a   Leong, Stanley P L ^a   Minor, David ^a   Billings, Paul R ^c   Soroceanu, Liliana ^a   Debs, Robert ^a   Miller, James R ^a   Sagebiel, Richard W ^a   Kashani Sabet, Mohammed ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of California San Francisco ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; BROMODOMAIN PHD FINGER TRANSCRIPTION FACTOR; DABRAFENIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BCL XL; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, MOUSE; CELL NUCLEUS ANTIGEN; FETAL ALZHEIMER ANTIGEN; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; NERVE PROTEIN; OXIME; SULFONAMIDE; TUMOR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER SIZE; CARCINOGENESIS; CHROMATIN ASSEMBLY AND DISASSEMBLY; COLONY FORMATION; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; DISTANT METASTASIS FREE SURVIVAL; DRUG SENSITIVITY; FEMALE; GENE DOSAGE; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MELANOMA; MELANOMA CELL LINE; METASTASIS POTENTIAL; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR INVASION; TUMOR XENOGRAFT; ANIMAL; C57BL MOUSE; DISEASE COURSE; DRUG EFFECTS; DRUG SCREENING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; METABOLISM; MUTATION; NUDE MOUSE; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; SKIN NEOPLASMS;

ANIMALS; ANTIGENS, NUCLEAR; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; IMIDAZOLES; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INDOLES; MELANOMA; MICE; MICE, INBRED C57BL; MICE, NUDE; MOLECULAR TARGETED THERAPY; MUTATION; NERVE TISSUE PROTEINS; OXIMES; PROTO-ONCOGENE PROTEINS B-RAF; REAL-TIME POLYMERASE CHAIN REACTION; SKIN NEOPLASMS; SULFONAMIDES; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84928436901     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv034     Document Type: Article

References (43)

1. Clapier CR, Cairns BR. The biology of chromatin remodeling complexes. Annu Rev Biochem. 2009;78;273-304.
2. Tsukiyama T, Wu C. Purification and properties of an ATP-dependent nucleosome remodeling factor. Cell. 1995;83(6):1011-1020.
3. Xiao H, Sandaltzopoulos R, Wang HM, et al. Dual functions of largest NURF subunit NURF301 in nucleosome sliding and transcription factor interactions. Mol Cell. 2001;8(3):531-543.
4. Landry J, Sharov AA, Piao Y, et al. Essential role of chromatin remodeling protein Bptf in early mouse embryos and embryonic stem cells. PLoS Genet. 2008;4(10):e1000241.
5. Kwon SY, Xiao H, Wu C, Badenhorst P. Alternative splicing of NURF301 generates distinct NURF chromatin remodeling complexes with altered modified histone binding specificities. PLoS Genet. 2009;5(7):e1000574.
6. Wysocka J, Swigut T, Xiao H, et al. A PHD finger of NURF couples histone H3 lysine 4 trimethylation with chromatin remodelling. Nature. 2006;442(7098):86-90.
7. Reeves R, Nissen MS. The A. T-DNA-binding domain of mammalian high mobility group I chromosomal proteins. A novel peptide motif for recognizing DNA structure. J Biol Chem. 1990;265(15):8573-8582.
8. Li H, Ilin S, Wang W, et al. Molecular basis for site-specific read-out of histone H3K4me3 by the BPTF PHD finger of NURF. Nature. 2006;442(7098):91-95.
9. Haqq C, Nosrati M, Sudilovsky D, et al. The gene expression signatures of melanoma progression. Proc Natl Acad Sci USA. 2005;102(17):6092-6097.
10. Kallioniemi A, Kallioniemi OP, Piper J, et al. Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc Natl Acad Sci USA. 1994;91(6):2156-2160.
11. Solinas-Toldo S, Wallrapp C, Muller-Pillasch F, Bentz M, Gress T, Lichter P. Mapping of chromosomal imbalances in pancreatic carcinoma by comparative genomic hybridization. Cancer Res. 1996;56(16):3803-3807.
12. Richter J, Jiang F, Gorog JP, et al. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res. 1997;57(14):2860-2864.
13. Buganim Y, Goldstein I, Lipson D, et al. A novel translocation breakpoint within the BPTF gene is associated with a pre-malignant phenotype. PLoS One. 2010;5(3):e9657.
14. Mu X, Springer JE, Bowser R. FAC1 expression and localization in motor neurons of developing, adult, and amyotrophic lateral sclerosis spinal cord. Exp Neurol. 1997;146(1):17-24.
15. Jordan-Sciutto KL, Dragich JM, Bowser R. DNA binding activity of the fetal Alz-50 clone 1 (FAC1) protein is enhanced by phosphorylation. Biochem Biophys Res. Commun 1999;260(3):785-789.
16. Choudhary P, Varga-Weisz P. ATP-dependent chromatin remodelling: Action and reaction. Subcell Biochem 2007;41:29-43.
17. Ho L, Crabtree GR. Chromatin remodelling during development. Nature. 2010;463(7280):474-484.
18. Dar AA, Majid S, de Semir D, Nosrati M, Bezrookove V, Kashani-Sabet M. miRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein. J Biol Chem. 2011;286(19):16606-16614.
19. Dar AA, Majid S, Rittsteuer C, et al. The role of miR-18b in MDM2-p53 pathway signaling and melanoma progression. J Natl Cancer Inst. 2013;105(6):433-442.
20. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for highthroughput molecular profiling of tumor specimens. Nat Med. 1998;4(7):844-847.
21. Kashani-Sabet M, Shaikh L, Miller JR, 3rd, et al. NF-kappa B in the vascular progression of melanoma. J Clin Oncol. 2004;22(4):617-623.
22. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA. 2001;98(9):5116-5121.
23. Boucher MJ, Morisset J, Vachon PH, Reed JC, Laine J, Rivard N. MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem. 2000;79(3):355-369.
24. Greger JG, Eastman SD, Zhang V, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther. 2012;11(4):909-920.
25. Joseph EW, Pratilas CA, Poulikakos PI, et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci USA. 2010;107(33):14903-14908.
26. Ryan RJ, Bernstein BE. Molecular biology. Genetic events that shape the cancer epigenome. Science. 2012;336(6088):1513-1514.
27. Fujimoto A, Totoki Y, Abe T, et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet. 2012;44(7):760-764.
28. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363(16):1532-1543.
29. Jones S, Li M, Parsons DW, et al. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat. 2012;33(1):100-103.
30. Schwendel A, Langreck H, Reichel M, et al. Primary small-cell lung carcinomas and their metastases are characterized by a recurrent pattern of genetic alterations. Int J Cancer. 1997;74(1):86-93.
31. Sonoda G, Palazzo J, du Manoir S, et al. Comparative genomic hybridization detects frequent overrepresentation of chromosomal material from 3q26, 8q24, and 20q13 in human ovarian carcinomas. Genes Chromosomes Cancer. 1997;20(4):320-328.
32. Landry JW, Banerjee S, Taylor B, Aplan PD, Singer A, Wu C. Chromatin remodeling complex NURF regulates thymocyte maturation. Genes Dev. 2011;25(3):275-286.
33. Trisciuoglio D, Desideri M, Ciuffreda L, et al. Bcl-2 overexpression in melanoma cells increases tumor progression-associated properties and in vivo tumor growth. J Cell Physiol. 2005;205(3):414-421.
34. Zhou C, Mao XP, Guo Q, Zeng FQ. Diallyl trisulphide-induced apoptosis in human melanoma cells involves downregulation of Bcl-2 and Bcl-xL expression and activation of caspases. Clin Exp Dermatol. 2009;34(8):e537-e543.
35. Liu SC, Bassi DE, Zhang SY, Holoran D, Conti CJ, Klein-Szanto AJ. Overexpression of cyclin D2 is associated with increased in vivo invasiveness of human squamous carcinoma cells. Mol Carcinog. 2002;34(3):131-139.
36. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107-114.
37. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358-365.
38. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468(7326):973-977.
39. Villanueva J, Vultur A, Lee JT, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010;18(6):683-695.
40. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883-892.
41. Wei X, Walia V, Lin JC, et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet. 2011;43(5):442-446.
42. Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067-1073.
43. Nair HB, Bhaskaran S, Pathak S, et al. 1205-Lu Human Metastatic Melanoma Cells, not Human! J Cancer Sci Ther. 2013;5;119-119.